monday.com (NASDAQ:MNDY – Get Free Report) and Cellebrite DI (NASDAQ:CLBT – Get Free Report) are both mid-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability.
Valuation and Earnings
This table compares monday.com and Cellebrite DI”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| monday.com | $1.23 billion | 3.63 | $118.74 million | $2.35 | 37.24 |
| Cellebrite DI | $475.67 million | 5.84 | $78.33 million | $0.28 | 39.79 |
Profitability
This table compares monday.com and Cellebrite DI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| monday.com | 8.87% | 9.09% | 4.73% |
| Cellebrite DI | 11.43% | 16.04% | 8.49% |
Insider and Institutional Ownership
73.7% of monday.com shares are owned by institutional investors. Comparatively, 45.9% of Cellebrite DI shares are owned by institutional investors. 22.3% of monday.com shares are owned by company insiders. Comparatively, 5.7% of Cellebrite DI shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Risk and Volatility
monday.com has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, Cellebrite DI has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for monday.com and Cellebrite DI, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| monday.com | 1 | 9 | 14 | 1 | 2.60 |
| Cellebrite DI | 1 | 0 | 5 | 0 | 2.67 |
monday.com currently has a consensus target price of $117.91, indicating a potential upside of 34.73%. Cellebrite DI has a consensus target price of $16.70, indicating a potential upside of 49.91%. Given Cellebrite DI’s stronger consensus rating and higher probable upside, analysts clearly believe Cellebrite DI is more favorable than monday.com.
Summary
monday.com beats Cellebrite DI on 8 of the 15 factors compared between the two stocks.
About monday.com
monday.com Ltd., together with its subsidiaries, develops software applications in the United States, Europe, the Middle East, Africa, the United Kingdom, and internationally. The company provides Work OS, a cloud-based visual work operating system that consists of modular building blocks used and assembled to create software applications and work management tools. Its products include monday work management that manages workflows, projects, and portfolios for team collaboration and productivity; monday sales CRM, whcih tracks and manages various sales cycle; monday dev that builds agile product and software development workflows; WorkCanvas, a digital whiteboard; and WorkForms, which allows users to create personalized forms or surveys and gain organizational insights. It serves organizations, educational or government institution, and distinct business unit of an organization. The company was formerly known as DaPulse Labs Ltd. and changed its name to monday.com Ltd. in December 2017. monday.com Ltd. was incorporated in 2012 and is headquartered in Tel Aviv, Israel.
About Cellebrite DI
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft. It provides Inseyets, a digital forensics software that collects and reviews digital evidence from various digital sources when conducting legally sanctioned investigations. The company's digital forensics software also offers data extraction, decoding capabilities, workflows, and automation capabilities. In addition, it provides Cellebrite Pathfinder, which reduces the time spent manually reviewing digital evidence by automating data analysis and visualization; Smart Search, an open source intelligence tool that automates the collection and review of publicly available online data; and Guardian, a case and evidence management solution. Further, the company offers digital forensic software for enterprises and service providers, including Inseyets for Enterprise, Endpoint Inspector, and Mobile Now; and professional services, such as training and certification services, and other services. It serves federal and state and local agencies. The company was incorporated in 1999 and is headquartered in Petah Tikva, Israel.
Receive News & Ratings for monday.com Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for monday.com and related companies with MarketBeat.com's FREE daily email newsletter.
